NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance

NEUROONE MEDICAL TECHNOLOGIES Corp

Revenue overstated by ~$0.5M, net loss understated by ~$0.3M for quarter ended March 31, 2026.
Restatement caused by customer order modification at quarter-end; no prior periods affected.
Company reaffirms FY2026 product revenue guidance of at least $10.5M.
Internal control weakness identified; measures to improve controls are being implemented.
Audit Committee determined non-reliance on previously filed Form 10-Q for March 31, 2026.

item 4.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-060600
form_type: 8-K
ticker: NMTC
cik: 0001500198
company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
filed_at: 2026-05-22T20:30:28+00:00
discovered_at: 2026-05-22T20:33:00.300582+00:00
generated_at: 2026-05-22T20:47:03.594220+00:00
sec_items: ["4.02", "7.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-060600
json_url: https://secwatch.observer/filing/0001213900-26-060600.json
markdown_url: https://secwatch.observer/filing/0001213900-26-060600.md
text_url: https://secwatch.observer/filing/0001213900-26-060600.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390026060600/0001213900-26-060600-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390026060600/ea0291925-8k_neuroone.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-26-060600

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.